Partial Breast Irradiation Versus Whole Breast Irradiation for Early Breast Cancer Patients in a Randomized Phase III Trial: The Danish Breast Cancer Group Partial Breast Irradiation Trial

Author(s): Birgitte V. Offersen, MD, PhD1,2;Jan Alsner, MSc, PhD1;Hanne M. Nielsen, MD, PhD2;Erik H. Jakobsen, MD3;Mette H. Nielsen, MD, PhD4;Lars Stenbygaard, MD5;Anders N. Pedersen, MD, PhD6;Mette S. Thomsen, MSc, PhD7;Esben Yates, MSc7;Martin Berg, MSc8;Ebbe L. Lorenzen, MSc, PhD4;Ingelise Jensen, MSc9;Mirjana Josipovic, MSc, PhD6;Maj-Britt Jensen, MSc10;and Jens Overgaard, MD, DMSc1;on behalf of the Danish Breast Cancer Group Radiotherapy Committee
Source: DOI: 10.1200/JCO.22.00451 Journal of Clinical Oncology 40, no. 36 (December 20, 2022) 4189-4197.
Maem Hussein MD

Dr. Maen Hussein's Thoughts

For low-risk patients, less radiation is as good, I would love to hear input from Rad Onc. I did notice that the Rad Oncs I work with are adopting this.


On the basis of low risk of local recurrence in elderly patients with breast cancer after conservative surgery followed by whole breast irradiation (WBI), the Danish Breast Cancer Group initiated the noninferiority external-beam partial breast irradiation (PBI) trial ( identifier: NCT00892814). We hypothesized that PBI was noninferior to WBI regarding breast induration.


Patients operated with breast conservation for relatively low-risk breast cancer were randomly assigned to WBI versus PBI, and all had 40 Gy/15 fractions. The primary end point was 3-year grade 2-3 breast induration.


In total, 865 evaluable patients (434 WBI and 431 PBI) were enrolled between 2009 and 2016. Median follow-up was 5.0 years (morbidity) and 7.6 years (locoregional recurrence). The 3-year rate of induration was 9.7% for WBI and 5.1% for PBI (P = .014). Large breast size was significantly associated with induration with a 3-year incidence of 13% (WBI) and 6% (PBI) for large-breasted patients versus 6% (WBI) and 5% (PBI) for small-breasted patients. PBI showed no increased risk of dyspigmentation, telangiectasia, edema, or pain, and patient satisfaction was high. Letrozole and smoking did not increase the risk of radiation-associated morbidity. Sixteen patients had a locoregional recurrence (six WBI and 10 PBI; P = .28), 20 patients had a contralateral breast cancer, and eight patients had distant failure (five WBI and three PBI). A nonbreast second cancer was detected in 73 patients (8.4%), and there was no difference between groups.


External-beam PBI for patients with low-risk breast cancer was noninferior to WBI in terms of breast induration. Large breast size was a risk factor for radiation-associated induration. Few recurrences were detected and unrelated to PBI.

Author Affiliations

1Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark 2Department of Oncology, Aarhus University Hospital, Aarhus, Denmark 3Department of Oncology, Lillebaelt Hospital, Vejle, Denmark 4Department of Oncology, Odense University Hospital, Odense, Denmark 5Department of Oncology, Aalborg University Hospital, Aalborg, Denmark 6Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark 7Department of Medical Physics, Aarhus University Hospital, Aarhus, Denmark 8Department of Medical Physics, Lillebaelt Hospital, Vejle, Denmark 9Department of Medical Physics, Aalborg University Hospital, Aalborg, Denmark 10Danish Breast Cancer Group, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Articles

Final results of RIGHT Choice: Ribociclib plus endocrine therapy vs combination chemotherapy in premenopausal women with clinically aggressive HR+/HER2− advanced breast cancer

Nicely done study comparing Ribociclib + ET vs chemotherapy in premenopausal high-risk HR+, HER2-neg patients felt to be high risk. Results showed better efficacy (PFS), tolerability and similar response rates. Of note, >80% of patients had visceral disease or were felt to be rapid progressors. Anti-hormone-based therapy remains king in the HR+ setting.

Read More »

PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer

Findings from the PACE study show that the addition of Palbociclib to Fulvestrant was not better than Fulvestrant alone, and the addition of Avelumab to Fulvestrant improved and nearly doubled the PFS. This is compelling and should be studied further for our patients with HR+ HER2- MBC.

Read More »

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

This is a study showing tumor agnostic activity of trastuzumab deruxtecan (T-DXd) with an all-comer overall response rate (ORR) of 37.1%, duration of response (DOR) of 11.3 months and an overall survival (OS) of 13.4 months in an otherwise heavily pre-treated group. Those with IHC-3+ derived larger benefit than 2+. Patients with ERBB2 mutations who had no expression of HER2 were excluded from the trial.

Read More »